NEW!

Most patients with AR are not treated according to guidelines and adherence to treatment is poor. This has prompted the development of next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) – a refined ARIA initiative that emphasises integrated patient-centred care. 

This module aims to provide doctors with an overview of the management of AR and the positioning of a single-dose azelastine–fluticasone propionate combination (MPAze-Flu) according to next-generation ARIA.

NOTE :

Please read thoroughly & understand the module before attempting the assessment questions.

Terms & Conditions: 

■ Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point. 
■ MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points. 


The modules/articles are best viewed with:

Google Chrome, Firefox, Internet Explorer, Safari or any other W3C standards compliant browser
may be required to view the modules.